TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to keep lymphoma at bay after transplant
Disease control Recruiting nowThis study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental CAR T-Cell combo aims to stop lymphoma relapse after transplant
Disease control Recruiting nowThis early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC